The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.
Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.
The USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following segments:
Type of payment of licensing agreements
- Upfront payments
- Milestone payments
Type of protein degrader
- SARDs / SERDs
- Specific BET and DUB inhibitors
- Other protein degraders
- Neurodegenerative disorders
- Oncological disorders
- Other therapeutic areas
Route of administration
- Other routes
Key geographical region
- North America
Get Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Also Visit Our Latest Publication
This post was created with our nice and easy submission form. Create your post!